HRMY Stock Forecast & Price Target

Harmony Biosciences Hldgs is supported by a durable commercial engine in WAKIX, with 2026 net revenue reaffirmed at $1.00 billion–$1.04 billion and 3Q26/WAKIX revenue expected around $274.5 million, reflecting continued strong execution in narcolepsy. Its positive outlook is further reinforced by a cash-rich balance sheet, including $962.5 million in cash, cash equivalents, and investments at June, which gives management flexibility to fund development and selective business development while protecting WAKIX exclusivity. Beyond the core franchise, the pipeline offers multiple upside drivers, including BP-205’s 4Q26 MAD readout and later-stage assets such as EPX-100 and pitolisant in additional rare CNS indications, while the CEO transition appears orderly and continuity-preserving rather than disruptive.

Harmony Biosciences Hldgs is facing a fragile outlook because its valuation depends heavily on WAKIX growth, yet new patient adds could slow more than expected and additional competition in the sodium oxybate market may pressure demand. The bearish case is reinforced by meaningful pipeline uncertainty: clinical trials in PWS, DM1, DS/LGS, and Fragile X syndrome may fail, while pitolisant GR and EPX-100 carry substantial development and commercialization risk despite assigned success probabilities of 60% to 80%. Its risk-adjusted DCF and SOTP valuation assumes a 12% discount rate, a 6.0x terminal multiple, and about $3.2 billion in firm value, but ongoing ANDA and AET/Sandoz litigation, reimbursement risk, and possible earlier generic pitolisant competition threaten those assumptions.